Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 Mn\5R4VtdCCYaXHibYxqfHliQYPzZZk> NHjKVpgzNjVvMUWgcm0> MYW3NkBp MleybY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NVvOPIdTOjV5OUC5NFc>
U2932  MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWnEZ4JGOi53LUG1JI5O MYq3NkBp MmntbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NVHt[W53OjV5OUC5NFc>
OCI-LY7 MnPJR4VtdCCYaXHibYxqfHliQYPzZZk> MUeyMlUuOTVibl2= Mon3O|IhcA>? MVHpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh Mk\KNlU4QTB7MEe=
Farage NE\QcndE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2XrOlIvPS1zNTDuUS=> MojEO|IhcA>? Mlq3bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NFHENXozPTd7MEmwOy=>
LY7/EBV MkixR4VtdCCYaXHibYxqfHliQYPzZZk> NHjmZ40zNjVvMUWgcm0> M17XdVczKGh? MYPpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NYKyO4lPOjV5OUC5NFc>
U2932/EBV MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWWyMlUuOTVibl2= Mm[xO|IhcA>? M37Kd4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NX\uS4VWOjV5OUC5NFc>
HCT116 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P4elUuPTByMDDuUS=> MXOyOEBp NYrU[oNGTE2VTx?= NYTW[XJ1cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MlyzNlU1QTJ3MUW=
ACH-2 NVTVPYdRTnWwY4Tpc44hSXO|YYm= M4rUNlEuQSCwTR?= NF;ScGIzPCCq Mor2bY5lfWOnczDITXYuOSCHbo[g[ZhxemW|c3nvci=> MnO1NlUyPDl2Nke=
MCF-10A MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG4fWVKSzVyPUCuNVfDuTBwMEGgcm0> M3noWlI1QTV2OEW2
MCF-7 M4PvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TtdmlEPTB;MT6xNOKyOC5{MDDuUS=> MYWyOFk2PDh3Nh?=
SK-BR-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz0TWM2OD1zLkCwxtExNjN3IH7N MojoNlQ6PTR6NU[=
MDA-MB-231 M1q2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\sSJhzUUN3ME2wMlY5yrFyLkG0JI5O MWKyOFk2PDh3Nh?=
PC3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnWyTWM2OD1zLk[1xtExNjN3IH7N M1v2OlI1QTV2OEW2
HCT116 NHq0dI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITMTIlKSzVyPUGuNFDDuTBwMECgcm0> MljNNlQ6PTR6NU[=
HCT116-p21-/- MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfJcplDUUN3ME2xMlI3yrFyLkO3JI5O M{TNRVI1QTV2OEW2
S1 NInlXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTdwNkhCtVAvOjlibl2= M2DPbVI1QTV2OEW2
SW620 NIXwelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwOURCtVAvOjlibl2= NIHFdnUzPDl3NEi1Oi=>
LOX-IMVI NVPuOZE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwOEhCtVAvODNibl2= MUOyOFk2PDh3Nh?=
UACC-62 NF;IWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwNUdCtVAvOTZibl2= MnrYNlQ6PTR6NU[=
MDA-MB-435 M1zRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwOUFCtVAvODZibl2= NYjaVm9EOjR7NUS4OVY>
SF-295 M3fHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwOElCtVAvOTVibl2= MXWyOFk2PDh3Nh?=
A549 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLETWM2OD1zLkK2xtExNjJ2IH7N NHSwVHQzPDl3NEi1Oi=>
H460 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJwNUlCtVAvQDBibl2= MoO1NlQ6PTR6NU[=
EKVX NHrwOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwM{RCtVAvOzRibl2= NG\BNWIzPDl3NEi1Oi=>
H146 M4HkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMkNCtVAvODdibl2= MoXMNlQ6PTR6NU[=
H526 M1PUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nCbWlEPTB;MD6xOeKyOC5yMzDuUS=> NX\xPFE{OjR7NUS4OVY>
HuT-78 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTaOHJpUUN3ME2xMlc{yrFyLkS0JI5O MYmyOFk2PDh3Nh?=
HA NVjBepoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;heWU4OC54MkWtNVBvVQ>? M1n2PVQ5KGh? NGjscJRqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? MXGyOFc4OTVzMB?=
MS-275 M2q4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTMcIYxNjZ{NT2xNI5O NVnBZ|B7PDhiaB?= MluybY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> NWLUOXB1OjR5N{G1NVA>
CD4 T M4Htcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n0c|Q5KGh? MWTFR|UxRTRwNdMxNU4xKG6P NXzMNIpoOjR5MkK0OVQ>
CD4 T M3j4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDjSm9YPDhiaB?= NF:xR3pESzVyPUGwO:KyOTJ4IH7N NXS3PIlxOjR5MkK0OVQ>
CD4+ T NFXFb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzEZWhETUN3ME2zJI5O NILubW0zPDR7NUGwOS=>
A549 NF\VbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6xNQKBmzFyMNMgcm0> NVrTbWRKOjRxM{[vOFghcA>? M1W1SolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NXnuXIRwOjR2OEW3PVk>
JJN3 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO1XlEzPC92ODDo Mk\USWM2ODxz4pEJcm08KDR64pEJbC=> MWiyOFA{ODF3MB?=
OPM-2 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTWeVNqOjRxNEigbC=> M4fEW2VEPTC|PUJihKlvVTtiNElihKlp NWnTXYlQOjRyM{CxOVA>
RPMI-8226 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSyOE81QCCq NWPnSYJlTUN3MIO9NU456oDLbl27JFQ56oDLaB?= NEC3bVQzPDB|MEG1NC=>
U266 M3LxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7iNlQwPDhiaB?= MXHFR|Uxez1zMPMAjY5OQyB2OPMAjYg> M3jOfVI1ODNyMUWw
CA46 NIfYcllCeG:ydH;zbZMhSXO|YYm= MnLJOkBp NX;mfJdCcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NFnqcngzOzl4NkG2OC=>
DG75 MV3BdI9xfG:|aYOgRZN{[Xl? MoXkOkBp M4LMUolv\HWlZYOgco8h[XCxcITvd4l{ MWeyN|k3PjF4NB?=
Ramos NFLZUVVCeG:ydH;zbZMhSXO|YYm= MYW2JIg> NX7wS3pvcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ NISwR|IzOzl4NkG2OC=>
ST486 NX70V|NGSXCxcITvd4l{KEG|c3H5 M3n6UVYhcA>? M2e3Rolv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> MYWyN|k3PjF4NB?=
HuT78 NX;Bbo42SXCxcITvd4l{KEG|c3H5 NUjpTnF2OS9zMD:xNFAhdk1? MoXJOFghcA>? MnjNbY5lfWOnczDhdI9xfG:|aYOgZZQhOSCwTR?= MWeyN|U{Ojd|Mh?=
DpVp35 NYXPR4tJSXCxcITvd4l{KEG|c3H5 NU\uPIVnOS9zMD:xNFAhdk1? M{\TXlQ5KGh? MmLIbY5lfWOnczDicJVvfCCjcH;weI9{cXN? MU[yN|U{Ojd|Mh?=
DpVp50 M3H0fWFxd3C2b4Ppd{BCe3OjeR?= MnXUNU8yOC9zMECgcm0> NHrYRmo1QCCq MXzpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NULXcYF[OjN3M{K3N|I>
DpP75  MX\BdI9xfG:|aYOgRZN{[Xl? M17J[|EwOTBxMUCwJI5O MmXBOFghcA>? M4\UdYlv\HWlZYOgZox2dnRiYYDvdJRwe2m| M1;3NFI{PTN{N{Oy
SKOV-3 NFH0dpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi2Oo8y6oDVMkDuUS=> NFrCeIc4OiCq MYnEUXNQ NVLu[4xXemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MVuyN|AyODN2OB?=
Brca1 WT NIGyWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYex5qCUOjCwTR?= MXK3NkBp M{f6W2ROW09? MXHy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MoTSNlMxOTB|NEi=
Brca1 Null M4LaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjtTnp{OeLCk{Kwcm0> MVu3NkBp MmPxSG1UVw>? MUDy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MoW2NlMxOTB|NEi=
OVCAR-8  NV;HOVExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu1[3p2OeLCk{Kwcm0> MmHXO|IhcA>? M{PhZWROW09? MX3y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MmfhNlMxOTB|NEi=
NCI/ADR-RES MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[w[Wcy6oDVMkDuUS=> NEPy[JA4OiCq MYHEUXNQ NWn4UWlEemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NFzZO3gzOzBzMEO0PC=>
HCT116 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f3NlUhdk1vNUCg{txO NG\ocYczPCCq MnvJSG1UVw>? NX3vR|c3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NVjpboF6OjJ7MkS5OVg>
RKO M1vydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW1JI5ONTVyIN88US=> Mlu4NlQhcA>? NETR[WJFVVOR MnO5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MX6yNlkzPDl3OB?=
CO115 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH4OUBvVS13MDFOwG0> MoraNlQhcA>? MmqxSG1UVw>? NIPOZ5lqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MYqyNlkzPDl3OB?=
HFS M{CzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi1JI5O MknHNlQwPDhxN{KgbC=> M1j0O4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NVn3OItkOjJzME[yPFI>
LNCaP MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7MOUBvVQ>? NU[5fo01OjRxNEivO|IhcA>? NGLiUFdqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MWCyNlExPjJ6Mh?=
A549 Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\YOUBvVQ>? MUOyOE81QC95MjDo Mn\PbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> NHLwfZMzOjFyNkK4Ni=>
697  MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm4ToJKSzVy4pEJQgKBkTJwNdMgcm0> NXj5N2c{OjF3M{iyNVY>
697-R Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\ITWM2OOLCiU5ihKk5NjcEoH7NxsA> NXqxU442OjF3M{iyNVY>
HUT78 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFibl2= NHi4SFkzOTF7OEW0OS=>
THJ-16T NULteIxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO4R5AyKG6P MkXUNlQhcA>? M37Be4lvcGmkaYTzJINmdGxiZ4Lve5Rp MXeyNFgyODV4OB?=
HCT116 MlvESpVv[3Srb36gRZN{[Xl? NVzNdFM5OjBibl2= MoXSPEBp MoL4cY9lfWyjdHXzJJRz[W6|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w MnjxNlA4Ozl2NUS=
B104  NG\sb5pHfW6ldHnvckBCe3OjeR?= M33ydVIhdk1? MV:yOE81QC95MjDo NHHqVJJqdmO{ZXHz[ZMhfGinIIP1doZi[2ViZYjwdoV{e2mxbjDv[kBETDJywrC= M1rhfVIxPjh4NUC1
HL-60  Ml7kR5l1d3SxeHnjbZR6KEG|c3H5 NV3UcYt[OS13MECgcm0> NW[weGx2OjRiaB?= NHvi[GVqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NX3IW3N4OjB4MkSxOlM>
HP100 MlTNR5l1d3SxeHnjbZR6KEG|c3H5 NVzBcIx1OS13MECgcm0> Ml3VNlQhcA>? M4rvO4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M37SblIxPjJ2MU[z
HL-60  Mn;KSpVv[3Srb36gRZN{[Xl? NEXYW|AyOCCwTR?= MVu0M|YwOTZiaB?= MWDpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? MUeyNFYzPDF4Mx?=
HP100 M1jqXWZ2dmO2aX;uJGF{e2G7 MVGxNEBvVQ>? NUnjPFlXPC94L{G2JIg> MWXpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? MmjENlA3OjRzNkO=
HL-60  M3XyUWZ2dmO2aX;uJGF{e2G7 MnnaNVAuPTByIH7N NVnMd4VYPCCq MoLv[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi NVrQVHlNOjB4MkSxOlM>
HP100 NYHIZotuTnWwY4Tpc44hSXO|YYm= MkH1NVAuPTByIH7N NG\mOIg1KGh? MVfk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? M3P2[|IxPjJ2MU[z
11z M3zWfmtqdmG|ZTDBd5NigQ>? NXm2c4dzOy1zMECgcm0> MmWydoVlfWOnczDISGFEKGWweontZZRq[yCjY4Tpeol1gSBqSVO1NOKhRSB4LkWgxtEhOC54IH7tc4wwVCl? M325e|IxPjB3MUS0
SKOV-3 NVz3cIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj5R2N7PC96L{G2JI5O MVy0PEBp NHP2NFVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NFf5TXozODRyNEW2OC=>
OVCAR-3 MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf4OE85NzF4IH7N NX\1b5NsPDhiaB?= NYTPPGtlcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MnfsNlA1ODR3NkS=
HBL-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PzUVIuOTBibl2= MVGyOEBp MnHoTWM2OD12LkOgcm0> Ml3zNlAxPjhyOEC=
Jeko-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP3Nk02OCCwTR?= Mnm0NlQhcA>? NEPpeGtKSzVyPUGxJI5O M4LNelIxODZ6MEiw
Granta-519 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYe1MVQxKG6P NXPtc3JGOjRiaB?= NXfKT2ZMUUN3ME21PE42KG6P MkHCNlAxPjhyOEC=
L1236 NIPTS5BEgXSxdH;4bYNqfHliQYPzZZk> MXixJI5ONTFyMDFOwG0> MljSOFghcA>? MUHFR|UxRTBwMEeg{txO MnjRNVkzOzN2N{C=
L428 MoXvR5l1d3SxeHnjbZR6KEG|c3H5 M1\JNlEhdk1vMUCwJO69VQ>? NEG1OHc1QCCq M1zjV2VEPTB;MD60N{DPxE1? NX24[VlpOTl{M{O0O|A>
KM-H2 MXHDfZRwfG:6aXPpeJkhSXO|YYm= NGL6VpcyKG6PLUGwNEDPxE1? Mmf4OFghcA>? NX3HOnM6TUN3ME2wMlU5KM7:TR?= NWr3XIRSOTl{M{O0O|A>
L540Cy MkTGR5l1d3SxeHnjbZR6KEG|c3H5 NF;wb5UyKG6PLUGwNEDPxE1? NF;ROok1QCCq MV\FR|UxRTBwMU[g{txO Ml[0NVkzOzN2N{C=
G401 MW\GeY5kfGmxbjDBd5NigQ>? M33U[|ExKG6P MoXFNlQwPDhxN{KgbC=> MmDCSG1UVw>? NVfocYhNcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v MXexPVIzOTV6Nh?=
STM91-01 NY\oVppXTnWwY4Tpc44hSXO|YYm= NYD0bVlGOTBibl2= NHXMRVYzPC92OD:3NkBp M1T6OGROW09? MlrvbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NEPBdIcyQTJ{MUW4Oi=>
SJSC  NVLmSJBnTnWwY4Tpc44hSXO|YYm= MYGxNEBvVQ>? NIjoWFAzPC92OD:3NkBp M4nTPWROW09? MXTpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= M2Py[FE6OjJzNUi2
BT16  Mn\5SpVv[3Srb36gRZN{[Xl? NXy4VWpSOTBibl2= MljHNlQwPDhxN{KgbC=> MV7EUXNQ MkfYbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MVyxPVIzOTV6Nh?=
NCI-H1299 M2LUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnhTWM2OD12LkdCtVAvOiCwZz;tcC=> NUG3ZmlyOTlzN{m4PVA>
NCI-2882 NGDyU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvwOmpKSzVyPUGuOuKyOC5yNDDu[{9udA>? M17aVFE6OTd7OEmw
HCC95 MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXYcJAyUUN3ME2yMlXDuTBwMEWgcocwdWx? MWWxPVE4QTh7MB?=
NCI-H23 NGLCWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwOdMxNE4zKG6pL33s NWLKWWZlOTlzN{m4PVA>
NCI-H157 NXrsS4RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NECwT25KSzVyPUGuOuKyOC5yMjDu[{9udA>? M{LlbVE6OTd7OEmw
NCI-H460 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7xTWM2OD1{LkJCtVAvODdibnevcYw> M1HCPVE6OTd7OEmw
NCI-H1975 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TCSGlEPTB;MT6zxtExNjB2IH7nM41t MUKxPVE4QTh7MB?=
NCI-H820 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{niVWlEPTB;Mj60xtExNjFibnevcYw> MknFNVkyPzl6OUC=
NCI-H1650 NG\HZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\KWWlEPTB;ND65xtExNjNibnevcYw> NF3nXXIyQTF5OUi5NC=>
DTC1 M1jFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwNUGgcm0> MojrNVg2PjZ{NE[=
KAO MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7VTWM2OD1yLkmxJI5O M{\0NVE5PTZ4MkS2
SU-CCS-1 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzKXXBHUUN3ME2wMlg6KG6P NX\oNYd1OTh3Nk[yOFY>
SYO-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojkTWM2OD1yLk[3JI5O NGnVb|UyQDV4NkK0Oi=>
FUJI MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnlOphvUUN3ME2xMlMyKG6P NUDSVnU5OTh3Nk[yOFY>
SKNMC NWTwXodkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFwMUegcm0> MYOxPFU3PjJ2Nh?=
402-91 M2jlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwMk[gcm0> NX;Kfo1GOTh3Nk[yOFY>
1765-92 NHjOWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfQTWM2OD1zLke3JI5O MkX0NVg2PjZ{NE[=
JN-DSRCT-1 NVTrdlMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTyTWM2OD1zLkK1JI5O MkjYNVg2PjZ{NE[=
NMS-2PC MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILx[3lKSzVyPUCuPFEhdk1? MkTpNVg2PjZ{NE[=
HL60 M3Xx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzpTWM2OD1zLki2JI5O Ml\aNVg2PjZ{NE[=
A549 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX6TWM2OD1|LkK0JI5O MojzNVg2PjZ{NE[=
SW480 MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwNkmgcm0> NUfQZm15OTh3Nk[yOFY>
MCF7 MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvwTWM2OD1|LkW1JI5O M{nmeFE5PTZ4MkS2
PC-3 NUnUNoViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHyOpZ2UUN3ME2yMlUyKG6P NYr0T49kOTh3Nk[yOFY>
MMRU MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G1bmlEPTB;Mj61O{BvVQ>? M3;FUVE5PTZ4MkS2
Hs68 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHvOnI{UUN3ME2+NVAhdk1? M2DP[VE5PTZ4MkS2
hMSC-001F NGK5eGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRT5zMDDuUS=> MXqxPFU3PjJ2Nh?=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID